December 19, 2018
1 min read

Endoanchor system effective in AAA, hostile aortic necks

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

An endoanchor system effectively treated patients with complex anatomy, including hostile aortic necks, requiring intervention for an abdominal aortic aneurysm, according to 3-year data from the ANCHOR registry presented at VEITHSymposium.

William D. Jordan Jr., MD, professor of surgery and chief of the division of vascular surgery and endovascular therapy at Emory University School of Medicine, presented data from a subset of patients from the registry with short, hostile aortic neck anatomies.

All patients were implanted with the endoanchor system (Heli-FX EndoAnchor System, Medtronic) in combination with various endovascular stent grafts. Most were implanted prophylactically (n = 120), but some received the implant after failed endovascular aneurysm repair (n = 41), according to a press release from Medtronic.

Mean neck length was 11.2 mm in the prophylactic group and 10.2 mm in the therapeutic revision group.

At 3 years, the rate of type 1a endoleaks was 1.7% in the prophylactic group and 2.4% in the therapeutic revision group, Jordan said during a presentation.

Positive sac stability and regression at 3 years was observed in 96.5% of the prophylactic group and 80% of the therapeutic revision group, according to the researchers.

According to Kaplan-Meier estimates, the 3-year rate of freedom from secondary procedures to treat type 1a endoleaks was 98.7% in the prophylactic group and 86.3% in the therapeutic revision group, and the 3-year rate of freedom from aneurysm-related mortality was 98.3% in the prophylactic group and 91.1% in the therapeutic revision group.

“Hostile aortic necks are frequently seen in clinical practice and have historically presented challenges for physicians treating patients through an endovascular approach,” Jordan said in the release. “With these data, we are continuing to validate that by using Heli-FX in these challenging cases, we have the ability to successfully treat this critical patient population and expand applicability of EVAR to those with complex aortic anatomies.” – by Erik Swain


Jordan WD Jr, et al. Session 61: New or Improved Devices and Developments to Treat Endoleaks and Prevent Migration: Endoanchors. Presented at: VEITHSymposium; Nov. 13-17, 2018; New York.

Disclosure: The study was funded by Medtronic. Jordan reports he receives institutional research grants from Bolton Medical, Cook Medical, Endologix, Medtronic, Trivascular and W.L. Gore and Associates, and institutional consultant fees from Cardinal Health, Medtronic and W.L. Gore and Associates.